MOLECULAR PARTNERS TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCHARE CONFERENCE IN NEW YORK Donnerstag, 07. September 2017 - 07:00
| Media Release (PDF) | ||||||||||||||||
MOLECULAR PARTNERS TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCHARE CONFERENCE IN NEW YORK | ||||||||||||||||
Zurich-Schlieren, September 07, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today announced that Dr. Patrick Amstutz, CEO and Andreas Emmenegger, CFO of Molecular Partners will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 4:40 PM Eastern Time (10:40 PM CET).
The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A replay of the webcast will be made available on the company's website www.molecularpartners.com under the Investors section. The replay will be available for 180 days following the presentation. | ||||||||||||||||
About Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For further details, please contact:
|